- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Hereditary angioedema
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1282KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 142KB)
Lanadelumab – July 2021
Lanadelumab: Solution for subcutaneous injection 300 mg in 2 mL; Takhzyro®
Last updated
29 October 2021